Alvogen
Tracked across 3 events · 27 articles · First seen Apr 30, 2026 · Last active Jun 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Alvogen, a global biotechnology company, announced that its Founder and Executive Chairman, Róbert Wessman, and Chief Strategy Officer, Dr. Balaji Srinivasan, will participate in three upcoming investor conferences in June 2026. These include the Jefferies…
Impact: Alvogen is the company presenting at multiple investor conferences, aiming to engage with investors and provide updates on its biosimilar development and commercialization efforts. This event offers a platform for Alvogen to enhance its visibility and potentially attract new investments.
Jun 02, 2026 · 6 articles
Business
Alvogen>>>, a biotechnology company, announced the resubmission of Biologics License Applications (BLAs) for AVT05 (a biosimilar to Simponi and Simponi Aria) and AVT06 (a biosimilar to Eylea) to the United States — Food and Drug…
Impact: Alvogen resubmitted Biologics License Applications for AVT05 and AVT06 to the United States — Food and Drug Administration>>> (FDA), which is a positive step towards potential market approval and commercialization of its biosimilar products. This action follows extensive work on manufacturing and quality systems.
Jun 04, 2026 · 10 articles
Regulatory
Alvogen>>> announced that the United States — Food and Drug Administration>>> has accepted for review its Biologics License Application (BLA) for AVT16. AVT16 is a proposed interchangeable biosimilar to Vedolizumab (vedolizumab), a biologic medicine used…
Impact: Alvogen announced that the United States — Food and Drug Administration>>> accepted its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Vedolizumab. This is a significant step for Alvogen>>> in expanding its biosimilar pipeline and market reach.
Jun 08, 2026 · 11 articles
100
Alvogen announced participationAlvotech to present at...
100
Alvogen resubmitted applications United States — Food and Drug AdministrationAlvotech resubmits AVT05,...
100
United States — Food and Drug Administration accepted Biologics License Application AlvogenAlvotech AVT16 BLA...
90
Alvogen announced acceptanceAlvotech AVT16 BLA...
80
United States — Food and Drug Administration conduct six-month review AlvogenAlvotech resubmits AVT05,...
60
Alvogen partnered Sun PharmaAlvotech AVT16 BLA...
60
Sun Pharma partnered AlvogenAlvotech AVT16 BLA...
40
Alvogen announced positive resultsAlvotech AVT16 BLA...
30
European Union — European Medicines Agency validated Marketing Authorization Application AlvogenAlvotech AVT16 BLA...
NEWSDESK
Track Alvogen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard